# Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations

Source: https://onco.cc/trials/nct07640295/  
OnCo record `nct07640295` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.

## Summary

Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations is a phase 1/2 interventional study registered as NCT07640295 by Jacobio Pharmaceuticals Co., Ltd., with 80 participants planned, started 2026-07-16 and due to reach its primary completion in 2029-12-31. Interventions recorded: JAB-23E73 tablet，nab-paclitaxel，gemcitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07640295
- Phase: 1/2
- Setting: A Multicenter, Phase Ib/III Study to Evaluate JAB-23E73 in Combination With Nab-Paclitaxel and Gemcitabine in Participants With Metastatic Pancreatic Ductal Adenocarcinoma Harboring KRAS Gene Alterations
- Sponsor: Jacobio Pharmaceuticals Co., Ltd.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT07640295: https://clinicaltrials.gov/study/NCT07640295

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/)
- companies: [Jacobio Pharmaceuticals](https://onco.cc/companies/jacobio-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct07640295.json